Table 4. Details of Response and Follow-up for Patients Treated with Bevacizumab.

Patient No.	Response	Characteristics of response	Patient status
1	CR	7.4 cm vaginal apex mass, resolved after RT/bevacizumab	NED at 8.5 months after start of bevacizumab
2	PR	Upper abdominal disease and liver mass, stable when bevacizumab was combined with gemcitabine, progression when bevacizumab was combined with leuprolide acetate, and PR when bevacizumab was combined with docetaxel	AWD 25.5 months after start of bevacizumab
3	PR	PR of abdominopelvic disease with eventual progression	AWD 13.5 months after start of bevacizumab
4	Stable	Stable disease when combined with paclitaxel and carboplatin or combined with liposomal doxorubicin	AWD 21.6 months after start of bevacizumab
5	Stable	Mixed response with decrease in liver lesions but increase in peritoneal implant and ascites; did not meet criteria for response or progression	DOD 9.4 months after start of bevacizumab
6	Progression	Peritoneal implant, lung metastasis, and diaphragmatic lymph node involvement progressed at 3 months	AWD 25.7 months after start of bevacizumab
7	Progression	Progression in liver and lung	AWD 37.3 months after start of bevacizumab
8	Progression	Abdominopelvic disease progressed; liver lesion decreased but likely owing to recent liver RT and so considered progression	DOD 28.9 months after start of bevacizumab

CR: complete response; RT: radiotherapy; PR: partial response; NED: no evidence of disease; AWD: alive with disease; DOD: died of disease